Karuna Therapeutics

$99.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.01 (+2.05%) Today
-$0.45 (-0.45%) As of 10:00 PM UTC after-hours

Why Robinhood?

You can buy or sell KRTX and other stocks, options, and ETFs commission-free!

About KRTX

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders.The company was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA. The listed name for KRTX is Karuna Therapeutics, Inc. Common Stock.

CEO
Steven Marc Paul
Employees
19
Headquarters
Boston, Massachusetts
Founded
2009
Market Cap
2.68B
Price-Earnings Ratio
Dividend Yield
Average Volume
159.36K
High Today
$101.60
Low Today
$98.00
Open Price
$98.78
Volume
117.64K
52 Week High
$123.73
52 Week Low
$52.62

Collections

KRTX Earnings

-$146.02
-$97.35
-$48.67
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 23, Pre-Market

You May Also Like